ENHANCED ORAL BIOAVAILABILITY IN ALBINO RABBITS OF LOVASTATIN NANOPARTICLES
Abstract
The aim of the study was to compare the single dose oral bioavailability of lovastatin (LV) nanoparticles in albino rabbits. Plasma was analyzed for lovastatin using a sensitive, reproducible, accurate and validated RP-HPLC method. Pharmacokinetic parameters including AUC, Cmax, Tmax, t1/2, MRT and Kel were determined from plasma concentration of the formulations. The randomly divided into three treatment groups with six animals in each group, as standard I, Standard II and Test. Lovastatin pure drug and lovastatin lovastatin marketed formulation were administered to standard group. Lovastatin loaded nanoparticles suspension was administered to test group.  The Cmax of LV nanoparticles was found to be 72.28 ±0.158 ng/ml, whereas Cmax value for the drug suspension and marketed tablet formulation was found to be 33.10 ± 0.176ng/ml and 40.96 ± 0.244ng/ml respectively. (P < 0.001) indicating facilitated absorption of LV by nanoparticles. Tmax of lovastatin nanoparticles was 2 hrs, whereas for the drug suspension and marketed tablet formulation were 1 h respectively. (P < 0.001)
The AUC (0–∞h) value for the lovastatin nanoparticles, drug suspension and marketed tablet formulation were found to be 301.43 ±0.165 (ng/ml × h), 73.88 ± 0.210 (ng/ml × h) and  120.51 ± 0.338 (ng/ml × h) respectively. (p < 0.001) The mean residence time (MRT) values for the lovastatin nanoparticles, drug suspension and marketed tablet formulation were found to be 1.41 h, 1.35 h and 1.63 h respectively. (P < 0.001)  The relative bioavailability was found to be significant improvement in bioavailability (1.5 fold) as compared with the conventional tablets.
DOI
https://doi.org/10.22270/jddt.v4i3-s.866Published
Abstract Display: 494 
PDF Downloads: 1755 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.